BMS-142
BMS-142 is a PDL1 inhibitor (IC50 = 96.7 nM) (kd = 13.2 nM) . BMS-142 can reduce the survival rate of acute T-lymphoblastic leukemia cells and ovarian cancer cells. BMS-142 can be used in research on cancers such as acute T-lymphoblastic leukemia and ovarian cancer[1].
Product Specifications
CAS Number
1675203-24-3
UNSPSC
12352005
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
N#CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
Molecular Formula
C25H26N2O4
Molecular Weight
418.48
References & Citations
[1]Ganesan A, et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. 2019 Aug 27;9 (1) :12392. d
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6461576-01 0.2 mL
ADCY8, ID (Ca(2+)/Calmodulin-activated Adenylyl Cyclase, Adenylyl Cyclase 8, ATP Pyrophosphate-lyase 8, Adenylate Cyclase Type VIII, Adenylate Cyclase Type 8) (AP)
Sign In for Pricing
View Details MBS6461576-02 5x 0.2 mL
ADCY8, ID (Ca(2+)/Calmodulin-activated Adenylyl Cyclase, Adenylyl Cyclase 8, ATP Pyrophosphate-lyase 8, Adenylate Cyclase Type VIII, Adenylate Cyclase Type 8) (AP)
Sign In for Pricing
View Details